Global First! Medicilon Powers Tyercan’s Breakthrough Anti-Tumor Protein-Drug Tye1001 to U.S. and China IND Clearance

On February 26, Tyercan announced that its independently developed first-in-class drug, Tye1001, received clinical trial approval from China’s NMPA, following its approval by the US FDA on July 12, 2024. This marks a significant milestone of dual approval in both China and the US. As Tyercan’s partner, Medicilon delivered comprehensive GLP-compliant preclinical services, including pharmacodynamics, […]

Medicilon Supports Partner Nuoyuan Medical Equipment Co., Ltd. in Securing FDA IND Approval for Class 1 Innovation Drug Pemefolacianine

  2025-01-07 On December 20, Nanjing Nuoyuan Medical Devices Co., Ltd. (“Nuoyuan Medical”) received FDA approval for an IND application for Pemefolacianine, an innovative Class 1 drug. This marks the first FDA IND approval for a folate receptor-targeted imaging agent developed in China, following Cytalux (OTL-38), the world’s first FDA-approved agent of its kind. Pemefolacianine has […]

A Decade of Collaboration: Medicilon Supports SinoRDA in Achieving Approval for Linaprazan Glurate

2025-01-02 On December 3, Shanghai SinoRDA Science and Technology Co., Ltd., a subsidiary of Guizhou SinoRDA Biotechnology Co., Ltd. (SinoRDA), secured approval from the National Medical Products Administration for its Linaprazan Glurate capsules. This milestone drug, a Category 1 chemical medication, is designed to treat reflux esophagitis. Medicilon, a trusted partner of SinoRDA for over a […]

Medicilon Supports Strategic Partner CGeneTech in Achieving Approval for Next-Generation DPP-4 Inhibitor

2025-01-02 CGeneTech Biopharmaceutical Technology (Suzhou) Co., Ltd. (“CGeneTech”) recently marked a significant milestone with the approval of its innovative Class 1 drug, Sentagliptin Phosphate tablets, for marketing in China. As a strategic partner, Medicilon provided comprehensive preclinical research services that complied with GLP standards, encompassing pharmacodynamics, pharmacokinetics, safety evaluations, and biomarker bioanalysis in Phase I clinical trials. Medicilon’s reliable research system—demonstrating high consistency […]

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon’s technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions. Dr. Lilly Xu Chief Technology Officer of Medicilon […]

Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres

2024-12-03 Recently, JM045 sustained-release microspheres, independently developed by the Institute of Innovative Pharmaceuticals under Jemincare Pharmaceutical Group, received clinical trial approval. Medicilon, as a trusted partner, provided pharmacokinetic studies and GLP-compliant safety evaluations, playing an instrumental role in advancing the drug development process. JM045: A New Hope for Prostate Cancer Patients JM045 is a gonadotropin-releasing hormone (GnRH) analog […]

Medicilon Boston’s Second R&D Center Grandly Sets Sail

2024-11-19 On November 15th, Medicilon proudly unveiled its second R&D center in Boston, a milestone that reinforces its commitment to global drug innovation and its strategic expansion into international markets. This achievement elevates Medicilon’s position as a competitive force in the pharmaceutical landscape while highlighting its dedication to quality and collaboration. The launch event brought […]

Medicilon Supports Jemincare’s JMX-2002 Liposome Injection Clinical Trial Approval

2024-12-09 Shanghai, China – October 16, 2024 – Medicilon is pleased to announce that its long-term partner, Jemincare Group Co., Ltd. (“Jemincare”), has received clinical trial approval from the China National Medical Products Administration (NMPA) for its innovative liposome injection drug, JMX-2002, for the treatment of solid tumors, including non-small cell lung cancer and breast cancer. […]

Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts

2024-08-29 In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and toxicology studies. This milestone heralds Medicilon’s continued global business expansion. Medicilon’s U.S. R&D Center The Lexington, MA location was chosen to enhance synergy and […]

Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout

2024-03-11 Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times. Over the past 20 years, Medicilon has been involved in the development of 421 new drug and generic drug projects that have obtained IND […]